Antipyrine, coumarin and glipizide affect n-acetylation measured by caffeine test

I. Klebovich, A. Rautio, P. Salonpää, P. Arvela, O. Pelkonen, EA A. Sotaniemi

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The effect of various treatments on acetylation status measured by caffeine metabolites was investigated in 17 subjects with non-insulin dependent diabetes mellitus (NIDDM). The test drugs, caffeine (200 mg), antipyrine (20 mg/kg) and coumarin (5 mg), were given simultaneously, and urinary 5-acetylamino-6-formyl-amino-3-methyluracil/1-methylxanthine (AFMU/1X) molar ratio was measured before and after 8 weeks of therapy. The urinary AFMU/1X molar ratio decreased (p <0.05) after 8 weeks of therapy with glipizide (2.5 mg), but remained unaltered in those treated with placebo or those who self-monitored blood glucose (SMBG) by glucometer. Antipyrine and coumarin decreased (p <0.05) the AFMU/1X molar ratio both in diabetics and healthy volunteers. Our data demonstrate that glipizide, antipyrine and coumarin may interfere with the classification of acetylator status measured by caffeine metabolites.

Original languageEnglish
Pages (from-to)225-227
Number of pages3
JournalBiomedicine and Pharmacotherapy
Volume49
Issue number5
DOIs
Publication statusPublished - 1995

Fingerprint

Glipizide
Antipyrine
Acetylation
Caffeine
Type 2 Diabetes Mellitus
Blood Glucose
Healthy Volunteers
Therapeutics
Placebos
Pharmaceutical Preparations
5-acetylamino-6-amino-3-methyluracil
coumarin
1-methylxanthine

Keywords

  • acetylator status
  • drug therapy
  • non-insulin dependent diabetes mellitus

ASJC Scopus subject areas

  • Pharmacology

Cite this

Antipyrine, coumarin and glipizide affect n-acetylation measured by caffeine test. / Klebovich, I.; Rautio, A.; Salonpää, P.; Arvela, P.; Pelkonen, O.; Sotaniemi, EA A.

In: Biomedicine and Pharmacotherapy, Vol. 49, No. 5, 1995, p. 225-227.

Research output: Contribution to journalArticle

Klebovich, I. ; Rautio, A. ; Salonpää, P. ; Arvela, P. ; Pelkonen, O. ; Sotaniemi, EA A. / Antipyrine, coumarin and glipizide affect n-acetylation measured by caffeine test. In: Biomedicine and Pharmacotherapy. 1995 ; Vol. 49, No. 5. pp. 225-227.
@article{1b30523ab2f743d78dd3213b9e43e1ff,
title = "Antipyrine, coumarin and glipizide affect n-acetylation measured by caffeine test",
abstract = "The effect of various treatments on acetylation status measured by caffeine metabolites was investigated in 17 subjects with non-insulin dependent diabetes mellitus (NIDDM). The test drugs, caffeine (200 mg), antipyrine (20 mg/kg) and coumarin (5 mg), were given simultaneously, and urinary 5-acetylamino-6-formyl-amino-3-methyluracil/1-methylxanthine (AFMU/1X) molar ratio was measured before and after 8 weeks of therapy. The urinary AFMU/1X molar ratio decreased (p <0.05) after 8 weeks of therapy with glipizide (2.5 mg), but remained unaltered in those treated with placebo or those who self-monitored blood glucose (SMBG) by glucometer. Antipyrine and coumarin decreased (p <0.05) the AFMU/1X molar ratio both in diabetics and healthy volunteers. Our data demonstrate that glipizide, antipyrine and coumarin may interfere with the classification of acetylator status measured by caffeine metabolites.",
keywords = "acetylator status, drug therapy, non-insulin dependent diabetes mellitus",
author = "I. Klebovich and A. Rautio and P. Salonp{\"a}{\"a} and P. Arvela and O. Pelkonen and Sotaniemi, {EA A.}",
year = "1995",
doi = "10.1016/0753-3322(96)82627-8",
language = "English",
volume = "49",
pages = "225--227",
journal = "Biomedicine and Pharmacotherapy",
issn = "0753-3322",
publisher = "Elsevier Masson",
number = "5",

}

TY - JOUR

T1 - Antipyrine, coumarin and glipizide affect n-acetylation measured by caffeine test

AU - Klebovich, I.

AU - Rautio, A.

AU - Salonpää, P.

AU - Arvela, P.

AU - Pelkonen, O.

AU - Sotaniemi, EA A.

PY - 1995

Y1 - 1995

N2 - The effect of various treatments on acetylation status measured by caffeine metabolites was investigated in 17 subjects with non-insulin dependent diabetes mellitus (NIDDM). The test drugs, caffeine (200 mg), antipyrine (20 mg/kg) and coumarin (5 mg), were given simultaneously, and urinary 5-acetylamino-6-formyl-amino-3-methyluracil/1-methylxanthine (AFMU/1X) molar ratio was measured before and after 8 weeks of therapy. The urinary AFMU/1X molar ratio decreased (p <0.05) after 8 weeks of therapy with glipizide (2.5 mg), but remained unaltered in those treated with placebo or those who self-monitored blood glucose (SMBG) by glucometer. Antipyrine and coumarin decreased (p <0.05) the AFMU/1X molar ratio both in diabetics and healthy volunteers. Our data demonstrate that glipizide, antipyrine and coumarin may interfere with the classification of acetylator status measured by caffeine metabolites.

AB - The effect of various treatments on acetylation status measured by caffeine metabolites was investigated in 17 subjects with non-insulin dependent diabetes mellitus (NIDDM). The test drugs, caffeine (200 mg), antipyrine (20 mg/kg) and coumarin (5 mg), were given simultaneously, and urinary 5-acetylamino-6-formyl-amino-3-methyluracil/1-methylxanthine (AFMU/1X) molar ratio was measured before and after 8 weeks of therapy. The urinary AFMU/1X molar ratio decreased (p <0.05) after 8 weeks of therapy with glipizide (2.5 mg), but remained unaltered in those treated with placebo or those who self-monitored blood glucose (SMBG) by glucometer. Antipyrine and coumarin decreased (p <0.05) the AFMU/1X molar ratio both in diabetics and healthy volunteers. Our data demonstrate that glipizide, antipyrine and coumarin may interfere with the classification of acetylator status measured by caffeine metabolites.

KW - acetylator status

KW - drug therapy

KW - non-insulin dependent diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=0029168024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029168024&partnerID=8YFLogxK

U2 - 10.1016/0753-3322(96)82627-8

DO - 10.1016/0753-3322(96)82627-8

M3 - Article

C2 - 7579000

AN - SCOPUS:0029168024

VL - 49

SP - 225

EP - 227

JO - Biomedicine and Pharmacotherapy

JF - Biomedicine and Pharmacotherapy

SN - 0753-3322

IS - 5

ER -